Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism LILRB2 inhibitors(Leukocyte immunoglobulin-like receptor subfamily B member 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Elpiscience Biopharma Ltd.Startup |
Active Organization Elpiscience Biopharma Ltd.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 3 | CN | Elpiscience Biopharma Ltd.Startup | 16 Apr 2021 |
Locally Advanced Malignant Solid Neoplasm | Phase 1 | AU | Elpiscience Biopharma Ltd.Startup | 07 Sep 2023 |